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Hypertension is a major health problem worldwide. Its attendant morbidity and mortality complications have a great impact on
patient’s quality of life and survival. Optimizing blood pressure control has been shown to improve overall health outcomes. In
addition to pharmacological therapies, nonpharmacological approach such as dietary modification plays an important role in
controlling blood pressure. Many dietary components such as sodium, potassium, calcium, and magnesium have been studied
substantially in the past decades. While some of these nutrients have clear evidence for their recommendation, some remain
controversial and are still of ongoing study. Dietary modification is often discussed with patients and can provide a great benefit
in blood pressure regulation. As such, reviewing the current evidence will be very useful in guiding patients and their physician
and/or dietician in decision making. In this review article of nutritional factors in hypertension management, we aim to examine
the role of nutritional factors individually and as components of whole dietary patterns.

1. Introduction
In adults aged 18 years and older, hypertension is defined as a
systolic blood pressure (SBP) equal or more than 140 mmHg
and/or diastolic blood pressure (DBP) equal or more than
90 mmHg based on the mean of 2 or more properly measured
seated blood pressure readings on each of 2 or more office
visits by the seventh report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC) [1]. According to the 2012 World Health
Statistics report released by the World Health Organization
(WHO), hypertension affects approximately 24.8% of the
global population with the range from 19.7% to 35.5% in
different regions [2]. It is one of the most common diseases
that lead to office visits or hospitalizations and a major risk
factor for stroke, congestive heart failure (CHF), myocardial
infarction (MI), peripheral vascular disease, and overall
mortality. Many of those with hypertension are undiagnosed,

and of those detected, about two-thirds are suboptimally controlled [1]. Early treatment can improve blood pressure and its
complications significantly [1]. Therapeutic options include
diet and lifestyle changes (including weight loss, smoking
cessation, and increased physical activity), antihypertensive
drugs, and surgery in special situations.
Clinical and population-based studies show that several
components of the diet such as sodium, potassium, calcium, magnesium, fiber, and fish oil affect blood pressure,
and modification of these nutritional factors provide an
important strategy to control blood pressure especially in
the prehypertensive stage (SBP 120–139 mmHg and/or DBP
80–89 mmHg) or stage I hypertension (SBP 140–159 mmHg
and/or DBP 90–99 mmHg). The role of these dietary factors
singly or in combination in blood pressure regulation and to
what extent each contributes has been a subject of research
for many decades, and despite this, it remains controversial.
Modifying one’s diet can be a difficult and significant change

2
in life, and many patients oppose this or fail despite several
attempts. Given how frequently clinicians have to provide
patients with this recommendation and the potential impact
on the overall outcome in patient health, it is of great benefit
to study the current evidence in nutritional approach to
hypertension management. In this paper, we aim to review
the role of each individual dietary factor as well as whole
dietary patterns.

2. Sodium
The relationship between sodium intake and blood pressure changes has been a topic of discussion for decades.
Hypertension is predominantly observed in societies with
average sodium chloride intake >100 mmol/day and very rare
in populations consuming <50 mmol/day [3, 4]. However, the
link between salt and hypertension is still an ongoing debate.
The concept of salt sensitivity versus salt resistance originated
from studies demonstrating heterogeneous blood pressure
responses to changes in sodium intake. These changes were
observed both in hypertensive and normotensive subjects [5–
8]. Till date, there is no uniformed definition of salt sensitivity
due to great variations in published studies regarding study
protocols, techniques, duration, and magnitude of sodium
intake and blood pressure changes. However, the most commonly used method was introduced by Weinberger [9]. Based
on mean arterial blood pressure response to sodium load by
intravenous administration of 2 liters of normal saline and
sodium depletion by a 10 mmol sodium diet and 3 doses of
oral furosemide (40 mg each), the authors arbitrarily classified salt sensitivity as a decrease in mean arterial pressure
≥10 mmHg and salt resistance as a decrease ≤5 mmHg when
comparing the 2 blood pressure measurements.
As a brief review of physiology, sodium homeostasis is
maintained by glomerular filtration and tubular reabsorption. Sixty-five to seventy-five percent of sodium reabsorption is mediated by neurohumoral hormone in the proximal
(angiotensin II and norepinephrine) and collecting tubules
(aldosterone, atrial natriuretic peptide), whereas 30–35%
occurs in the loop of Henle and distal tubules and this is
flow dependent. A parallel adaptation in renal tubular activity
in response to alterations in glomerular filtration of sodium
keeps little variation in urinary sodium excretion [10]. This
explains a steady range of sodium level even in cases of
advanced kidney failure.
Salt sensitivity has been found to have a higher prevalence
in certain populations: older age [11, 12], blacks [12], insulin
resistance [13, 14], microalbuminuria [15], chronic kidney
disease (CKD) [16], and low renin level [17, 18]. Recent animal
and molecular studies have suggested the contribution of
certain genetic polymorphisms to the development of salt
sensitive hypertension via different mechanisms: affecting
renal tubular Na+K+ATPase activity [19, 20], decreasing
dopamine receptor function in renal proximal tubule [21],
or altering endothelin receptor activity [22]. Salt sensitivity
has been reported to be an independent prognostic factor for
increased risk of left ventricular hypertrophy [23], cardiovascular events [24], and cumulative mortality [25], regardless of
blood pressure.
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Dietary sodium restriction is strongly advocated as a
lifestyle behavioral change for prevention and treatment of
hypertension and consequently cardiovascular morbidity and
mortality by several professional organizations [1, 26–28].
Despite an abundance of studies on its efficacy, results are
conflicting and naturally provoke questions on the benefits of
continuing to advocate this intervention to patients [29, 30].
Evidence from several clinical studies shows that a reduction in sodium intake leads to modest to large reduction
in blood pressure in normotensive and hypertensive participants [31–36] as well as decreased risk of cardiovascular
events [37–39].
The INTERSALT study, a population-based study across
52 centers from 32 countries, examined the relationship
between sodium excretion and blood pressure among over
10,000 participants. Sodium excretion was highly variable
(0.2–242 mmol/24 hour (hr)), with 4 centers having very
low levels (0.2–51.3 mmol/24 hr). A significant positive association between sodium excretion and blood pressure in
individuals was reported overall. However, with exclusion of
data from the 4 centers with the lowest excretion, no relation
could be found [4].
The Dietary Approaches to Stop Hypertension (DASH)sodium trial randomized subjects to either the DASH diet
(rich in fruits, vegetables, and low-fat dairy and reduced in
saturated and total fat) or a control diet (typical United States
(US) diet which is high in fat and low in fruits, vegetables,
and dairy products) with participants consuming a graded
sodium intake (high, intermediate, low) within each group
during the study period. The study demonstrated significant
dose-response decreases in SBP and DBP overall and blunting
of the age-related increase in blood pressure with sodium
restriction. The DASH diet and sodium restriction each
lowered blood pressure substantially, but the effect was
greater when combined [35, 36].
Investigators on a prospective followup study of participants in the trials of hypertension prevention phase I and II
for 10–15 years found a 30% and 20% risk reduction of cardiovascular disease (MI, stroke and coronary revascularization)
and cardiovascular death, respectively, but the reduction in
death was not statistically significant [37].
In contrast, several studies demonstrate harmful effects
of lower salt intake on important clinical outcomes including
MI [40], all-cause and cardiovascular mortality [41, 42],
sympathetic hormones [43, 44], fasting plasma glucose and
insulin levels [44, 45], cholesterol [43, 44, 46], and in addition, higher CHF readmissions and brain natriuretic peptide
levels [47, 48]. Higher mortality [49, 50] and development of
end stage renal disease (ESRD) [49] have also been reported
with lower sodium intake among diabetics.
All together, despite several years and high magnitude of
population-based studies and clinical research, the evidence
supporting the recommendation of dietary sodium restriction should be interpreted with caution.
Given that salt restriction is not a “one size fits all”
approach, differentiating individuals with salt sensitive and
salt resistant hypertension would be beneficial. However,
subjecting all hypertensive patients to salt sensitivity testing
as in research protocols seems inconvenient and unfeasible.
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Thus, the question appears to be how physicians can clinically
determine salt sensitivity. To address this query, a couple
of studies have suggested ambulatory, however, indirect
methods in evaluating salt responsiveness. De la Sierra and
coinvestigators reported that patient’s performance on ambulatory blood pressure monitoring could be a useful tool
to assess salt sensitivity [51]. In their study, salt sensitive
patients exhibited a nondipper profile on both low salt and
high salt diets, while salt resistant subjects with high salt
intake had increased blood pressure during sleep with no
significant changes in the 24-hr blood pressure. Galletti et
al. found that in salt sensitive patients, there was a strong
correlation between 24-hr urinary sodium excretion and
blood pressure changes [52]. In another study, involving 89
Caribbean Hispanic hypertensive patients, plasma renin level
was used to evaluate patient’s response to antihypertensive
therapy [53]. Sixty-two percent of the patients had low
renin essential hypertension and responded preferentially to
monotherapy with hydrochlorothiazide or calcium channel
blockers. A phase 4 randomized study testing Fludrocortisone administration in identifying salt sensitivity is currently
underway [54]. These methods need to be validated by larger
studies before being considered for routine tests in evaluating
and/or guiding treatment in hypertensive patients.
Currently, based on available evidence, the WHO strongly
recommends the restriction of daily sodium intake to less
than 2000 mg (or 5000 mg salt) [55], while the AHA advises
lower than 1500 mg sodium (or 3800 mg salt) per day [28].

3. Potassium
The association of potassium and blood pressure has been
described in many studies. Potassium intake was found to
be inversely related to both DBP and SBP in a populationbased study including 685 men and women who were predominantly Caucasian in Southern California, United States
of America (USA) [56]. Similar result was illustrated in the
Rotterdam Study [57], a big population-based study in which
3239 participants older than 55 years old were included.
Patients with an increase in potassium intake of 1000 mg/day
had a 0.9 mmHg lower SBP and a 0.8 mmHg lower DBP. In
a study by Krishna and Kapoor, potassium depletion was
shown to be associated with a decrease in sodium excretion,
plasma renin activity, and plasma aldosterone concentrations
and an increase of 7 mmHg in SBP and 6 mmHg in DBP [58].
Several interventional studies have shown the positive
effects of potassium supplementation on blood pressure
reduction. Cappuccio and MacGregor reviewed 19 clinical
trials in which oral potassium supplements significantly
lowered SBP (mean of −5.9 mmHg, 95% confidence internal
(CI), −6.6 to −5.2 mmHg) and DBP (mean of −3.4 mmHg,
95% CI, −4.0 to 2.8 mmHg) [59]. A meta-analysis consisting
of 27 potassium trials in adults with a minimum of 2 weeks
duration also demonstrated a change in blood pressure
with increased potassium intake: a mean of −2.42 mmHg
(95% CI, −3.75 to −1.08 mmHg) in SBP and −1.57 mmHg
(95% CI, −2.65 to −0.50 mmHg) in DBP pressure [60].
Dickinson and colleagues used stricter inclusion criteria and
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only selected 5 randomized controlled trials for their metaanalysis published in the Cochrane Database in 2006. The
authors did not find a statistical significant effect of potassium
supplementation on blood pressure. However, the argument
of small number of subjects, short duration of followup, and
substantial heterogeneity of these trials was discussed as a
possible explanation for the finding of this meta-analysis [61].
The benefit of potassium intake on blood pressure reduction appears to be greater in patients with hypertension [59,
60], longer duration of supplementation [59], and concurrent
high intake of sodium [62].
The magnitude of blood pressure reduction seems small
in number but might be translated into a benefit in mortality
from complications of hypertension. In a study of 6 different
populations, the relative increase in 25-year mortality risk due
to coronary heart disease was 1.17 (95% CI, 1.14 to 1.20) per
10 mmHg increase in SBP and 1.13 (95% CI, 1.10 to 1.15) per
5 mmHg increase in DBP. After adjustment for within-subject
variability in blood pressure, this relative risk was 1.28 [63]. A
5 mmHg decrease in DBP was reported to be associated with
less than one-third of strokes [64, 65].
It is worth mentioning that some protective effects of high
potassium intake on cardiovascular health might be independent of blood pressure. An analysis of sodium and potassium
intake and mortality among US adults based on data from
the third National Health and Nutrition Examination Survey
(NHANES) showed that higher sodium intake was associated
with increased all-cause mortality, while higher potassium
intake seemed to be associated with lower mortality. Of
note, this finding was independent of sex, age, hypertension,
physical activity, and body mass index (BMI) [66]. In a 12year prospective study, a 10 mmol increase in daily potassium
intake was associated with a 40% reduction in the risk of
stroke-associated mortality. This protective effect of potassium did not differ by other dietary variables and known
cardiovascular risk factors (age, sex, blood pressure, blood
cholesterol level, obesity, fasting blood glucose level, and
cigarette smoking) [67].
The antihypertensive effect of potassium supplementation might be from various mechanisms: (1) natriuresis by
inhibiting sodium reabsorption in the proximal renal tubules
[68] and suppressing renin secretion [69], (2) normalization
of the plasma level of digitalis like substance [70], (3)
increased urinary volume excretion [70], (4) smooth muscle
relaxation [71, 72] by increasing nitric oxide production [73]
and/or by stimulating the rectifier K(+) channels resulting
in potential membrane hyperpolarization and subsequently
vasodilation [74], (5) suppression of free radical formation
[75], and (6) protection against vascular injury in salt sensitive hypertension [76]. Which one of these mechanisms plays
a predominant role in the reduction of blood pressure and/or
cardiovascular mortality is not quite clear at this time.
Based on available data, the Institute of Medicine has
recommended a potassium intake of 4700 mg (120 mmol) a
day as adequate intake for all adults [77]. A similar amount
of daily potassium consumption was also suggested by the
American Heart Association (AHA) in 2006 to achieve the
potential benefit of blood pressure reduction [28]. The 2003
WHO/International Society of Hypertension statement on
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management of hypertension supported an increased dietary
potassium intake although a threshold was not specified
[78]. However, the suggested daily intake of potassium
might be lower in patients who are prone to developing
hyperkalemia such as those with impaired renal excretion
of potassium from CKD, CHF, adrenal insufficiency, and
medications use (angiotensin converting enzyme (ACE)
inhibitors, angiotensin receptor blockers (ARB), potassiumsparing diuretics, trimethoprim, cyclosporine, heparin, etc.)
These patients need to be monitored frequently.
In reality, the average intake of dietary potassium in many
countries is relatively lower than recommended. As in a
report from the third NHANES 1988–1994 study, estimated
mean potassium intakes of adults in the USA ranged from
2900 to 3300 mg in men and 2200 to 2400 mg in women [28].
The NHANES data from 2003 to 2008, the time span during
which the above recommendations were issued, revealed that
less than 2% of adults and approximately 5% of men in the
USA met the recommendations for potassium intake (i.e., at
least 4700 mg/day) [79]. In European countries, the average
daily potassium intake in adults was reported to be below
4700 mg. The number varied from 3200 mg to 4000 mg/day
in Finland [80] or from 2655 mg to 3371 mg/day in the United
Kingdom [81]. In China, the mean intake of potassium was
1950 mg/day in the urban and 1830 mg/day in the rural diet
[82].
Foods rich in potassium are vegetables, fruit, dairy
products, nuts, and so forth. Natural source of potassium
is preferable. Currently, pharmacological potassium supplementation is not recommended as a method to obtain the
advised daily intake of potassium.

4. Calcium
The relationship between calcium intake and hypertension is
a complex and difficult one to isolate largely because of the
interaction with other nutrients in the diets and difficulty
in reliably collecting calcium intake data and important
unmeasured confounding variables.
Despite an abundance of studies on the effect of dietary
or supplemental calcium on blood pressure, the evidence
on its benefit is inconclusive and remains controversial.
An inverse relationship between dietary calcium intake and
blood pressure has been reported in many studies [83–89].
Similarly, supplementation with 1000 mg calcium/day has
been demonstrated to lead to a decrease in blood pressure,
although results were inconsistent and mainly among hypertensives [90–92]. In contrast, other studies report minimal
to no effect of dietary calcium or supplementation on blood
pressure [93–99]. In addition, contradictory results have been
deduced from analysis of the same data as exemplified by the
Nurses’ Health Study [85, 94] and the NHANES [89, 100–103].
The differences in study results may be explained by a variety
of factors including heterogeneity of study participants, flaws
in study design, limitations in measurement of blood pressure
and calcium intake, short duration of studies, different
analytical methods, as well as collinearity with other dietary
factors such as magnesium, fiber, protein, and potassium.
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Two meta-analyses assessed the relationship between
dietary calcium supplementation and blood pressure. The
authors found small reductions in SBP (1-2 mmHg), and
results were even smaller and insignificant for DBP [104, 105].
Similar results were reported in another meta-analysis
by van Mierlo et al., effect on SBP of −1.86 mmHg (95% CI,
−2.91 to −0.81 mmHg) and DBP of −0.99 mmHg (95% CI,
−1.61 to −0.37 mmHg), however, the impact on SBP was larger
in people with relatively low calcium intake of ≤800 mg/day
[106]. A Cochrane review published in 2006 examined the
efficacy of oral calcium supplementation as a treatment for
hypertension. Only 13 randomized controlled trials with
a total of 485 participants with at least 8 weeks duration
were included. A statistically significant reduction in SBP
(−2.5 mmHg, 95% CI, −4.5 to −0.6 mmHg), but not DBP
(−0.8 mmHg, 95% CI, −2.1 to 0.4 mmHg), was found. Many
of the trials were of poor quality, and the authors concluded
that there was insufficient evidence to recommend calcium
supplementation as a treatment for hypertension [107].
Currently, the evidence on the benefit of calcium supplementation in prevention or treatment of hypertension is
weak; therefore, there is no justification to increase the intake
of calcium above the recommended dietary allowance of
1000–1300 mg/day based on age and gender. Foods rich in
calcium are mainly dairy products (preferably low fat) such
as milk, cheese, and yogurt.
Proposed mechanisms by which calcium intake regulates
blood pressure include alteration in intracellular calcium
which in turn affects vascular smooth muscle contraction
[108], effect of calcium metabolism and regulatory hormones
[109–111], increased natriuresis [112–114], and modulation
of the function of the sympathetic nervous system [113].
Interestingly, among people consuming low levels of calcium
in their diets, high salt intake is associated with higher
blood pressure levels [115–117], and it is suggested that the
hypertensive effect of a high sodium intake may be mitigated
by increasing dietary calcium [109, 112, 118, 119]. Resnick
also published extensively on the interlinking of the reninaldosterone system, calcium regulation, and salt sensitivity in
modulating blood pressure responses to salt loading, calcium
supplementation, and calcium channel blockers [120–125].
He suggested that these models may provide a targeted
approach to identifying and treating hypertensives with
calcium supplementation or calcium channel blockers based
on their serum renin level and salt sensitivity [126–128].

5. Magnesium
Magnesium deficiency has been found to result in increased
blood pressure in single studies [129, 130]. However, a metaanalysis looking at 29 observational studies points to a
negative correlation between dietary magnesium intake and
blood pressure [131].
The evidence of a causal association between magnesium
supplementation and blood pressure reduction was weak in
a meta-analysis including 12 randomized trials with followup
ranging from 8 to 26 weeks [132]. In another meta-analysis
with 20 studies, although a dose-response pattern was found,
magnesium intake only resulted in a small overall reduction
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in blood pressure, a mean of −0.6 mmHg (95% CI, −2.2 to
1.0 mmHg) for SBP and −0.8 mm Hg (95% CI, −1.9 to
0.4 mmHg) for DBP [133].
On the basis of these data, the relationship between
magnesium and hypertension seems inconsistent and not
convincing. Currently, magnesium supplementation is not
recommended as a means of hypertensive treatment.

6. Alcohol
A standard drink in the USA is equal to 14 g (6 ounces (oz)) of
pure alcohol. This amount is present in 12 oz of regular beer,
5 oz of wine (12% alcohol), 8 oz of malt liquor, and 1.5 oz of
80-proof distilled spirits [134]. This serving size can be varied
in different countries. In Britain or Australia, a unit of alcohol
contains 8 to 10 g [135], while in Japan, a drink contains 19.75 g
of alcohol. In this paper, we refer “a drink” to the US serving
size. Otherwise, the amount of alcohol will be specified.
Moderate alcohol intake, defined as a maximum of 2
alcoholic drinks/day in men and 1 alcoholic drink/day in
women and lighter-weight persons, is supported by the
AHA 2006 scientific statement of hypertension management
[28]. In a prospective cohort study involving 11,711 men
with preexisting hypertension, individuals who consumed a
moderate amount of alcohol tended to have a decreased risk
of MI. After adjustment for measurement error, BMI and
dietary variables, the hazard ratio for participants with MI per
12.5 g/day increment of alcohol intake was 0.68 (95% CI, 0.46
to 1.00) [136].
On the other hand, heavy drinking, generally referred
to as any amount of alcohol use above the moderate level,
is associated with a higher risk of hypertension in a dosedependent manner. This has been demonstrated in various
populations: Japanese men [137], US women [138], and both
men and women of different races [139]. The risk seems
more pronounced in individuals with a smaller BMI [137].
In the INTERSALT study, compared to nondrinkers, men
who drank 300–499 mL alcohol/week had higher SBP/DBP,
on average 2.7/1.6 mmHg. Women who drank at least
300 mL/week had blood pressures higher by 3.9/3.1 mmHg
than nondrinkers [140]. Alcohol reduction was associated
with a fall in blood pressure [141]. Available data supports that
moderate alcohol consumption should be recommended as
one of the components of hypertensive therapy.

7. Fiber
Fiber is the indigestible portion from plant-based food.
How exactly fiber might affect blood pressure is not entirely
understood. An inverse association between blood pressure and fiber intake has been described. Among 30,681
predominantly white US male health professionals, 40–75
years old, those with a fiber intake of less than 12 g/day
were at higher risk of developing hypertension compared
to those taking more than 24 g/day, relative risk 1.57 (95%
CI, 1.20 to 2.05) [88]. This relationship was independent of
other nutrients including sodium, potassium, calcium, and
magnesium. When the results of 24 randomized controlled
trials were evaluated, fiber supplementation with an average
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dose of 11.5 g/day modestly reduced SBP by −1.13 mmHg (95%
CI, −2.49 to 0.23 mmHg) and DBP by −1.26 mmHg (95% CI,
−2.04 to −0.48 mmHg). It seemed to have greater effect in
populations with hypertension and in those older than 40
years of age [142]. Similarly, a large randomized trial failed to
show a significant decrease in blood pressure with a high fiber
diet [143]. According to the 2006 scientific statement from the
AHA, there is insufficient evidence to recommend increased
dietary fiber intake alone for the reduction of blood pressure
[28].

8. Omega-3 Polyunsaturated Fatty Acid
(Fish Oil)
Daily dietary fish consumption as a part of weight reduction
regimens has shown benefits in blood pressure fall [144].
A body of evidence demonstrated the association between
concentrated Omega-3 polyunsaturated fatty acid extracted
from fish, hence usually known as “fish oil”, and blood
pressure reduction [145, 146]. This effect might have a dose
limit, as it was reported that fish oil did not change mean
blood pressure in the subjects who ate fish three or more
times a week as part of their usual diet, or in those who had a
baseline concentration of plasma phospholipid omega-3 fatty
acids above 175.1 mg/L [146]. Of note, these studies employed
large doses of Omega-3 polyunsaturated fatty acid (at least
3 g/day), which raises a concern of safety and side effects in
view of long-term use.
Mercury is a chemical element of which fish living in
contaminated water can contain a high level in their body.
Some cross-sectional studies have mentioned the possibility
of increasing blood pressure caused by mercury. Would this
go against the above findings of a positive correlation between
daily fish meal and blood pressure reduction? Recently, two
large prospective cohort studies on 6045 US men and women,
do not support any effects of methylmercury on the risk of
incident hypertension [147].

9. Garlic
Garlic is one of the most commonly used natural herbs. Its
role in hypertension has also been explored by researchers.
In patients with baseline elevated blood pressure, compared
with placebo, garlic significantly reduced SBP by 16.3 mmHg
(95% CI, 6.2 to 26.5 mmHg) and DBP by 9.3 mmHg (95% CI,
5.3 to 13.3 mmHg) [148]. The effect was repeatedly illustrated
in another meta-analysis [149]. Despite the potential advantage, the problem with nonstandardization in product preparation, formulas, and study heterogeneity does not allow
a conclusive message regarding garlic use in hypertensive
patients. It might be beneficial. However, how much, how
long, and which products to use are not clearly identified.

10. Products with Potential Harms
10.1. Caffeine. Being the main ingredient in stimulant drinks,
caffeine is found in coffee, tea, sodas, and many energy drinks.
Acutely, caffeine can elevate blood pressure in nonhabitual
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caffeine users [150], whereas little to no effect was seen in
habitual coffee drinkers [151, 152]. Chronic coffee drinkers
who have hypertension might not need to change their habit
based on the available data. Nevertheless, it can potentially be
harmful for irregular coffee drinkers.
There is evidence that other ingredient than caffeine
might be responsible for the stimulating effect of coffee on
blood pressure. An increase in blood pressure was observed
in decaffeinated coffee drinkers [153]. The use of caffeine
alone did not exert an elevated blood pressure in healthy
volunteers in a study [152].
10.2. Licorice. Licorice has been long used as a flavoring
agent in chewing tobacco, candies, spices, and as a medical product in some gastrointestinal and upper respiratory
disorders. It contains glycyrrhetinic acid which inhibits 11beta-hydroxysteroid dehydrogenase enzyme type 2 isoform,
allowing cortisol to bind to the mineralocorticoid receptors
creating a status of mineralocorticoid excess and subsequently blood pressure elevation. The use of licorice can be
potentially dangerous in hypertensive individuals [154].

11. Whole Dietary Pattern
11.1. DASH Diet. The DASH diet is a diet rich in fruits and
vegetables (4-5 servings/day) and low-fat dairy products (23 servings/day) and includes whole grains, poultry, fish, and
nuts. This diet is rich in potassium, magnesium, calcium,
dietary fiber, and protein and has reduced fat (total and
saturated) and cholesterol (<25%), red meat, sweets, and
sugar-containing beverages.
Two controlled clinical trials established its efficacy in
lowering blood pressure [35, 155]. The initial DASH trial [155]
enrolled 459 untreated participants with prehypertension
and stage I hypertension and randomly assigned them to
one of 3 groups (1) a control group which consumed a
typical US diet which was low in fruits, vegetables, and dairy
products and had a high fat content, (2) a diet rich in fruits
and vegetables, or (3) the DASH diet sodium intake and
body weight were held constant during the study period
of eight weeks. Compared with the control group, blood
pressure decreased by 5.5/3.0 mmHg and 2.8/1.1 mmHg in
the DASH diet and fruits-and-vegetables diet, respectively.
This reduction was higher among the subset of hypertensives
at 11.4/5.5 mmHg compared with 3.5/2.1 mmHg for those
without hypertension consuming the DASH diet. In addition,
the reduction in blood pressure began within two weeks and
was sustained for the next six weeks.
The DASH-sodium trial [35] was a crossover trial in
which 412 subjects were randomized to either the control
diet or DASH diet and 3 levels of sodium intake (low:
1.2 g/day, intermediate: 2.3 g/day, and high: 3.5 g/day) within
each diet arm for four weeks. Participants had SBP between
120 to 159 mmHg and DBP between 80 to 95 mmHg. Similar
to the earlier study, the DASH diet significantly lowered
blood pressure independent of sodium intake. With each
diet, reducing the sodium intake significantly decreased
blood pressure, and these effects persisted among those with
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and without hypertension, as well as across the different
races and sex. The combination of the DASH diet and low
sodium intake had the greatest impact, reducing SBP by
11.5/5.7 mmHg and 7.1/3.1 mmHg among hypertensives and
those without hypertension, respectively, compared with the
control diet and high sodium intake. The level of reduction
among hypertensives is comparable to that obtained with
drug monotherapy.
African Americans with hypertension derive the most
benefit from the blood pressure lowering effect of the DASH
diet [156], however they may be less likely to adhere to the
diet [157, 158]. Furthermore, the increase in blood pressure
with aging can be reduced by adopting the DASH diet with
sodium restriction [36, 159].
Other potential benefits of the DASH diet include reduction in cardiovascular morbidity [160, 161], mortality [162],
CHF events [163, 164], and cardiovascular risks factors [165–
167] as well as prevention of type 2 diabetes [168].
The DASH and low sodium diet has been endorsed by
professional organizations including the AHA [169], the JNC
[1], the American Association of Clinical Endocrinologists
[170], and the Canadian Hypertension Education Program
[27] for the prevention and treatment of hypertension.
Barriers to compliance with the DASH diet include cost,
availability, accessibility, lack of information, and cultural
dietary preferences. The US Department of Health and
Human Services published a guidebook, Your Guide to Lowering your Blood Pressure with DASH, which is a great resource
to guide patients in preparation of meals in accordance with
the DASH diet [171].
The PREMIER trial studied 810 adults with SBP ranging
from 120 to 159 mmHg and DBP 80 to 95 mmHg [172].
Patients were divided into 3 intervention groups: one-time
advice, “established” behavioral intervention based on the
established recommendations, and “established plus DASH.”
Food was prepared by participants and they were followed
up by telephone interview. The results showed that compared with the group receiving advice only, the 2 groups
with behavioral interventions had significant decrease in
the prevalence of hypertension and a higher percentage of
optimal blood pressure at 6 month followup. However, there
was no statistically significant difference between them.
11.2. Vegetarian Diet. Early observation has described lower
blood pressure in vegetarians compared to patients on regular
diets [173]. It seemed that sodium intake in vegetarian diet did
not contribute a significant effect to blood pressure changes
[174]. Recent studies also demonstrated that vegans do have
lower SBP and DBP and less likely to use antihypertensive
medications. In a study, for vegans, the odds ratio of hypertension compared with omnivores was 0.37 (95% CI, 0.19
to 0.74) [175]. Vegetarian diet with increased intake of fruit
and vegetables, polyunsaturated vegetable margarines, and
oils, fiber, calcium, and magnesium and decreased intake of
protein in mild untreated hypertensive patients resulted in
a fall of 5 mmHg in SBP. This diet improved blood pressure
without a change in urinary sodium or potassium excretion
or body weight [176]. Rouse and colleagues included 59
healthy normotensive patients in a randomized controlled
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study in which they were randomized to a control group
(omnivorous diet) and one of 2 experimental groups (omnivorous and/or lacto-ovo-vegetarian diet). Mean SBP dropped
by 5 to 6 mmHg and DBP dropped by 2 to 3 mmHg in the
group on vegetarian diet after adjustment for age, obesity,
heart rate, weight change, and blood pressure before dietary
change. Blood pressure rose substantially in subjects who
reverted to the omnivorous diet [177].
It appears that a vegetarian diet might reduce blood
pressure by several factors: increased vegetables, fiber and
fruit intake, low protein, and so forth.

12. Conclusion
Dietary modification has important therapeutic roles in
blood pressure control. Strong evidence supports the recommendation of a diet containing high potassium, moderate
alcohol, and high fiber intake. As a whole, a DASH pattern
diet rich in fruits, vegetables, low-fat dairy products, whole
grains, nuts, and fish with reduced amount of red meat, fat,
sugar-sweetened food and beverages, and/or a vegetarian
diet, which is also high in vegetables and fruits and low in animal protein should be considered. The use of pharmacological supplements to achieve these dietary goals is not advised.
Sodium restriction is strongly recommended by professional
organizations, however, this needs to be carefully interpreted
and individualized given the evidence of associated potential
harmful effects and its unequal efficacy in various patient
populations. The recommendation is not quite definite in
terms of increased intake of calcium, magnesium, fish oil, and
garlic. Irregular coffee drinkers and licorice consumers face a
possibility of inducing hypertension; thus, these habits need
to be avoided in patients at risk.
Established nutrition recommendations are proven to be
helpful in reducing blood pressure and thus hypertensionrelated complications and overall mortality. However, in view
of the heterogeneity in risk factors, patient features, and
pathogenesis of hypertension, the approach should be individualized and discussed in detail between the patient and
their physician and/or dietician, based on the understanding
of each patient’s distinct disease characteristics.
The importance of dietary modification in hypertension
management has been substantially studied for past decades
with encouraging findings. Additional studies are warranted
to further explore the role of these nutrient factors in
preventing and treating this condition in special populations.
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